Replies to post #172683 on Biotech Values

[DewDiligence]

Great presentation today by ENTA, very smooth and polished and great story/pipeline.

Yes, if this was the first time you’ve heard ENTA present; however, it was a carbon copy of ENTA’s other recent presentations.

I had expected Luly to address the BoD resignations in some manner, and perhaps he would have done so in the Q&A session. However, to my astonishment, no one at the Q&A session asked about the BoD resignations! Instead, the questions were rather clueless.

Any safety signals mentioned with any of the drug candidates?

None that I’m aware of. For the 3-DAA regimen of ABT-450 + ABT-267 + ABT-333 + ribavirin, the dropout rate in the SAPHIRE-1 and SAPHIRE-2 phase-3 studies was comparable to placebo (#msg-94169219, #msg-94817670).